Breast Cancer

Breast Cancer, Invasive Ductal

Invasive Mammary Carcinoma

Breast Cancer Stage I

Breast Cancer Stage IIA

The IORT component of this treatment is being delivered as per standard clinical practice. 20 Gy in one fraction will be delivered at the time of lumpectomy.

Intraoperative radiotherapy

James Graham Brown Cancer Center at the University of Louisville

Xoft® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer

A Prospective Observational Trial of Xoft® Intraoperative Radiotherapy (IORT) as a Component of Breast Conserving Therapy (BCT) in Patients With Early-Stage Breast Cancer

Adverse side effects of radiation grade 2 or higher as per CTCAE version 5.0

Breast cosmetic changes following IORT, assessed by the physician

Patient assessed breast cosmetic changes following IORT

Harriet Eldredge-Hindy

Assistant Professor of Radiation Oncology

University of Louisville

Postpartum Hemorrhage

Recruiting only pregnant women prior to child-birth delivery.

misoprostol

Queens Hospital Center

Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery

Effect of Adjunctive Misoprostol on Blood Loss at Vaginal Delivery

Aleksandr Fuks

Directore, Department OB / GYN , Queens Hospital Center

New York City Health and Hospitals Corporation

The treatment is planned using 2D wedges optimisation on the central CT-planning slice.

The treatment is planned 3D IMRT optimisation using all CT-planning slices.

Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.

Adjuvant breast radiotherapy

Vancouver Island Cancer Centre

Sunnybrook Odette Cancer Centre

Long Term Results of the Canadian Breast IMRT Study

Long Term Outcomes of a Multicentre Controlled Clinical Trial of Breast Irradiation Using Intensity-Modulated Radiation Therapy

Quantitatively patients will be asked if they have spontaneous breast pain in the treated breast during the last 6 months, and will be asked to rate its intensity using a Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (extreme pain).

Quantitatively pain intensity will be evaluated using the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE 4.0).

Qualitatively the pain will be evaluated and scored using the short form of the McGill pain questionnaire.

Skin and subcutaneous late radiation toxicity will be assessed by the clinical trial assistant using the European Organization for Research and Treatment of Cancer (EORTC) breast cancer rating system for the cosmesis assessment. This scale evaluates skin discoloration and oedema comparing between breasts as no, small, moderate or large differences.

The patient's cosmesis self-report will be used as most reliable cosmetic endpoint and will use the Breast Cancer Treatment Outcome Scale (BCTOS).

At time of initial treatment patient's quality of life was assessed at baseline, the last week of treatment, and 6 weeks after treatment using the European Organization for Research and Treatment of Cancer (EORTC) quality of life general module (C-30) self-assessment questionnaire. The same questionnaire will be administered to ensure consistency in the quality of life assessment and enable comparisons over time for individuals and cohorts.

Telangiectasia will be classified into four categories of surface: none, less than 1cm2, 1 to 4 cm2 and over 4cm2.

Induration will be evaluated using the Late Radiation Morbidity Scoring Scheme scale that classifies fibrosis in four grades.

Research assistant will use the four point scale European Organization for Research and Treatment of Cancer (EORTC) to evaluate cosmesis.

Digital photographs will be taken of the treated and untreated breasts and will be evaluated for cosmetic results by four blinded individuals using the EORTC criteria and the consensus score will be recorded.

At time of initial treatment patient's quality of life was assessed at baseline, the last week of treatment, and 6 weeks after treatment using the European Organization for Research and Treatment of Cancer (EORTC) quality of life breast module (BR-23) self-assessment questionnaire. The same questionnaire will be administered to ensure consistency in the quality of life assessment and enable comparisons over time for individuals and cohorts.

mastodynia/éidéime

Xoft® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer

Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery

Long Term Results of the Canadian Breast IMRT Study

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht